Clascoterone for treatment of acne
Aug 12,2024
What is Clascoterone?
Clascoterone is a novel topical anti-androgen drug that has been approved for the treatment of acne. Traditional oral anti-androgen therapies for acne, such as combined oral contraceptives and spironolactone, produce systemic hormonal effects and are generally not suitable for use in male patients, nor in some female patients. In contrast, Clascoterone is a first-in-class anti-androgen drug that has been shown to be both safe and effective in female and male patients over the age of 12. It is generally well tolerated except for occasional localised skin irritation, although in a Phase II clinical trial some adolescents showed biochemical evidence of HPA suppression, which disappeared after discontinuation of treatment.
Indications
Clascoterone is approved by the FDA for the topical treatment of acne vulgaris in patients 12 years of age and older. Clascoterone has also been found to be effective in treating
androgenetic alopecia in male subjects (aged 18–55 years) with
mild to moderate disease in the temple and vertex region. It
has not received FDA approval for this indication yet.
Mechanisms of action
Clascoterone competes with androgens (especially dihydrotestosterone) for binding to the androgen receptor and restricts its binding, thereby inhibiting downstream signalling in the acne pathway. It inhibits androgen receptor-regulated gene transcription and antagonises the production of lipids and inflammatory cytokines in human primary sebocytes with a dose-dependent manner.
Side effects
Common side effects of Clascoterone include: dryness at the site of application, flaking, erythema, hirsutism, acne, pain, contact dermatitis, hair colour change, eye irritation, peri-abdominal abscess, dysphonia, headache, oropharyngeal pain and allergy at the site of application. Elevated potassium levels have been observed in some study subjects. Long-term safety studies have shown that the drug does not produce systemic antiandrogenic effects such as hypogonadism or feminisation in male subjects.
References:
[1] CYRIAC MANJALY. Clascoterone for treatment of acne.[J]. Drugs of today, 2023. DOI:10.1358/dot.2023.59.2.3507749.
[2] PARVATHY SANTHOSH MD; Mamatha G M. Clascoterone: a new topical anti-androgen for acne management[J]. International Journal of Dermatology, 2021. DOI:10.1111/ijd.15752.
- Related articles
- Related Qustion
- Clascoterone: Introduction and Synthesis Dec 25, 2023
Clascoterone (cortexolone 17α-proprionate), a novel androgen receptor inhibitor, obtained its first approval by the USFDA in August 2020.
- Clascoterone skin care Dec 14, 2021
Clascoterone (cortexolone 17α-propionate, CB-03-01) is a novel antagonist of androgen receptors. It binds to androgen receptors with high affinity.
Dexamethasone is a glucocorticosteroid used in the treatment of different inflammatory conditions related to allergic disorders, skin conditions and lupus, psoriasis, ulcerative colitis, arthritis and respiratory disorders.....
Nov 13,2024APIDL-Serine, essential for metabolic function and neurological development, requires dietary intake due to insufficient synthesis, with sources including soy, eggs, and fish.....
Oct 21,2024APIClascoterone
19608-29-8You may like
- Clascoterone
- $43.00 / 25mg
- 2024-11-16
- CAS:19608-29-8
- Min. Order:
- Purity: 99.32%
- Supply Ability: 10g
- Clascoterone
- $100.00 / 50kg
- 2024-11-16
- CAS:19608-29-8
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: 5000Ton
- Clascoterone
- $0.00 / 25G
- 2024-11-15
- CAS:19608-29-8
- Min. Order: 25G
- Purity: 99%
- Supply Ability: 1000G